Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 10/20 | 0.92 |
| ▸ | GNAO1 | P09471 | 10/20 | 0.92 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.92 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319928 | 0.98 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL27763474 | 0.98 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL19604163 | 0.98 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL19604164 | 0.98 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL30092298 | 0.98 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL28793539 | 0.98 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL1070277 | 0.94 | GNAI3 (0.81) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL6247785 | 0.89 | GNAI3 (0.73) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL6097037 | 0.88 | GNAI3 (0.73) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL19606425 | 0.86 | GNAI3 (0.77) | GNAI3GNAO1GNAI1EPHX1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125729-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | Arete Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC | 2008-08-28 | — | — | US | claimed |
| WO-2008094862-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| EP-0927163-B1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-28 | — | — | EP | claimed |
| CN-1102927-C | Preparation method of 1-butyl-4-piperidyl methylamine | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | CN | claimed |
| US-6331631-B1 | Preparation of 1-butyl-4-piperidinylmethylamine | SMITHKLINE CORPORATION P.L.C. (GB) | 2001-12-18 | — | — | US | claimed |
| CN-1230179-A | Prepn. of 1-butyl-4-piperidinylmethylamine | SMITHKLINE BEECHAM PLC (GB) | 1999-09-29 | — | — | CN | claimed |
| EP-0927163-A1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | EP | claimed |
| WO-1998011067-A1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-03-19 | — | — | WO | claimed |
| WO-2023160039-A1 | β-ELEMENE DERIVATIVE WITH HDACI PHARMACOPHORE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州师范大学 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023003862-A1 | CXCR4 MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3383877-B1 | HETEROCYCLE COMPOUNDS AND USES THEREOF | ZHEJIANG JIANFENG YIEN BIOTECHNOLOGY CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| WO-2019238817-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING RPN11 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019013790-A1 | ANTIMICROBIAL COMPOUNDS AND USES THEREOF | CURZA GLOBAL, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-4197303-A | ANTIARRHYTHMIA AGENTS, ALKOXYCARBONYL ON 4-POSITION OF PIPERIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4197304-A | ANTIARRHYTHMIA AGENTS, N-PYRIDINYL-N-(4-ALKYLPIPERIDINYL)THIENYLACETAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4196210-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-01 | — | — | US | disclosed |
| US-4157393-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-06-05 | — | — | US | disclosed |
| US-4151286-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-04-24 | — | — | US | disclosed |
| US-4126689-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | UMPS, CPS1, NISCH | GNAI3 2651/4885GNAO1 2844/4885GNAI1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.